Origin Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Origin Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,600	Closed	-$1.45M	–	111
2021 Q2	$1.45M	Hold	2,600	–	–	0.16%	52
2021 Q1	$1.23M	Sell	2,600 -100	-4%	-$48.7K	0.13%	64
2020 Q4	$1.3M	Hold	2,700	–	–	0.12%	64
2020 Q3	$1.51M	Sell	2,700 -800	-23%	-$485K	0.16%	48
2020 Q2	$2.18M	Sell	3,500 -300	-8%	-$170K	0.32%	42
2020 Q1	$1.86M	Buy	+3,800	New	+$1.57M	0.24%	48
2019 Q2	–	Sell	-54,250	Closed	-$22.3M	–	131
2019 Q1	$22.3M	Buy	54,250 +17,000	+46%	+$7M	1.86%	13
2018 Q4	$13.9M	Buy	37,250 +1,050	+3%	+$384K	1.27%	32
2018 Q3	$14.6M	Buy	+36,200	New	+$13.8M	0.95%	47
2016 Q1	–	Sell	-50,425	Closed	-$27.4M	–	146
2015 Q4	$27.4M	Buy	50,425 +11,650	+30%	+$6.31M	2.22%	10
2015 Q3	$18M	Buy	+38,775	New	+$20.8M	1.49%	22

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Origin Asset Management's REGN Position: Q3 2021 in Review

Origin Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 2,600 shares — an estimated $1.45M sold.

Origin Asset Management first reported a position in REGN in Q3 2015 and held it in 11 quarters. The position peaked at $27.4M in Q4 2015. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Origin Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Origin Asset Management sold 2,600 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $1.45M.
Origin Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 11 quarters.
Origin Asset Management's Regeneron Pharmaceuticals position peaked at $27.4M in Q4 2015.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Origin Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.